Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Neel N, Ghobara Y, Turkmani M
REDEFINE 2 (obesity with type 2 diabetes) A phase 3a, 68-week, double-blind, placebo-controlled trial across 12 countries (NCT05394519 [11] ) in 1,206 adults with BMI 27, HbA 1c 710%, and type 2 diabetes, randomised 3:1 to CagriSema 2.4/2.4 mg (n=904) or placebo (n=302)
Ann N Y Acad Sci 1271:3743
Clinical trials show that while fat mass reduction predominates during semaglutide treatment, some lean mass loss does occur
US$ 23.84
US$ 24.70
US$ 25.87
US$ 21.31
US$ 28.43
US$ 26.98
